non » Trang Công Nghệ | Trangcongnghe.vn

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Globe Newswire

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Globenewswire -

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

Globe Newswire

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

Globenewswire -

Biggest Office Party Night of the Year Set for Unprecedented Surge in 0.0 Drinking

Globe Newswire

Biggest Office Party Night of the Year Set for Unprecedented Surge in 0.0 Drinking

Globenewswire -

Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica

Globe Newswire

Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica

Globenewswire -

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globe Newswire

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globenewswire -

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globe Newswire

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globenewswire -

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Globe Newswire

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Globenewswire -

XEM THÊM TIN MỚI